

Tommaso De Marchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4715248/publications.pdf>

Version: 2024-02-01

16
papers

463
citations

840776

11
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

1004
citing authors

#	ARTICLE	IF	CITATIONS
1	A somatic mutation in moesin drives progression into acute myeloid leukemia. <i>Science Advances</i> , 2022, 8, eabm9987.	10.3	2
2	Regulatory Interplay between miR-181a-5p and Estrogen Receptor Signaling Cascade in Breast Cancer. <i>Cancers</i> , 2021, 13, 543.	3.7	10
3	Proteogenomic Workflow Reveals Molecular Phenotypes Related to Breast Cancer Mammographic Appearance. <i>Journal of Proteome Research</i> , 2021, 20, 2983-3001.	3.7	14
4	Inhibition of Histone Demethylases LSD1 and UTX Regulates ER \pm Signaling in Breast Cancer. <i>Cancers</i> , 2019, 11, 2027.	3.7	34
5	Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer. <i>Scientific Reports</i> , 2017, 7, 2099.	3.3	33
6	The advantage of laser-capture microdissection over whole tissue analysis in proteomic profiling studies. <i>Proteomics</i> , 2016, 16, 1474-1485.	2.2	38
7	Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. <i>Drug Discovery Today</i> , 2016, 21, 1181-1188.	6.4	53
8	Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients. <i>Scientific Reports</i> , 2016, 6, 32027.	3.3	19
9	Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. <i>Journal of Proteome Research</i> , 2016, 15, 1230-1242.	3.7	21
10	4 α -protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. <i>Molecular Oncology</i> , 2016, 10, 24-39.	4.6	31
11	Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. <i>Oncotarget</i> , 2016, 7, 3098-3110.	1.8	26
12	Global proteomic characterization of microdissected estrogen receptor positive breast tumors. <i>Data in Brief</i> , 2015, 5, 399-402.	1.0	1
13	Antibody-Based Capture of Target Peptides in Multiple Reaction Monitoring Experiments. <i>Methods in Molecular Biology</i> , 2015, 1293, 123-135.	0.9	6
14	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt376.	6.3	77
15	Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1814-1827.	3.8	44
16	Quantitative Proteomic Analysis of Microdissected Breast Cancer Tissues: Comparison of Label-Free and SILAC-based Quantification with Shotgun, Directed, and Targeted MS Approaches. <i>Journal of Proteome Research</i> , 2013, 12, 4627-4641.	3.7	54